Treatment Of Aneurysmal Bone Cysts Research Articles

CT-guided radiofrequency ablation in patients with aneurysmal bone cysts

IntroductionAneurysmal bone cyst (ABC) is one of most therapeutic challenging lesions for orthopedic surgeons specially in large-sized lesions and lesions, which are very close to important neurovascular structures. In the present study, we express our experience in the treatment of aneurysmal bone cyst by radiofrequency thermal ablation (RFTA). MethodsIn the last two years, we have treated 20 cases (12 males & 8 females) presented with painful aneurysmal bone cysts in different anatomical locations, the age mean (±SD) is 18.95 ± 8.02 years and median is 17.5 years, the mean size of the lesions (±SD) is: 32.25 ± 7.15 mm & the median (range) is 33.5 mm (18.0–43.0) mm. The treatment was done by (RFTA) only in 11 cases and by (RFTA) with cementation in the other 9 cases, then the patients underwent close clinical follow-up for clinical symptoms by using visual analogue scale (VAS) pain score & radiological follow-up for one month, six months & one year after the procedure. ResultsClose follow-up for the patients proved that (RFTA) is a clinically successful &curative treatment as there was significant reduction in the mean (±SD) of the (VAS) pain score in all treated cases from 8.40 ± 1.23 before the intervention to 0.20 ± 0.41 at the end of follow-up period. No recorded post-procedural complications or recurrence during or at the end of the follow-up period.

Bisphosphonate therapy for spinal aneurysmal bone cysts

To assess the efficacy of bisphosphonate therapy in the management of spinal aneurysmal bone cysts (ABCs). A prospective study of six consecutive patients aged between 7 and 22years with spinal ABCs treated with pamidronate (1mg/kg) or zoledronate (4mg). A visual analogue scale (VAS) for pain and radiological (contrast-enhanced MRI and CT scan at 3 and 6months, then yearly X-rays) follow-up was continued for a minimum of 6years. One patient with an unstable C2/3 failed to respond to a single dose of bisphosphonate and required surgical resection and stabilisation with autologous bone grafting. Another, with a thoraco-lumbar ABC, experienced progression of neurological dysfunction after one cycle of bisphosphonate and, therefore, required surgical resection and stabilisation. In all other patients pain progressively improved and was resolved after two to four cycles (VAS 7.3-0). These patients all showed reduction in peri-lesional oedema and increased ossification by 3months. No patients have had a recurrence within the timeframe of this study. Bisphosphonate therapy can be used as the definitive treatment of spinal ABCs, except in patients with instability or progressive neurology, where surgical intervention is required. Clinicians should expect a patients symptoms to rapidly improve, their bone oedema to resolve by 3months and their lesion to partially or completely ossify by 6-12months.

Sclerotherapy using Surgiflo and alcohol: a new alternative for the treatment of aneurysmal bone cysts.

PurposeThis study aims to review the results of sclerotherapy using Surgiflo in addition to alcohol in primary aneurysmal bone cysts (ABC).MethodsA total of 16 consecutive patients with histologically confirmed diagnosis of primary ABC were treated by percutaneous Surgiflo and alcohol injection at our institution. Clinical follow-up included the assessment of pain, swelling, limping and functional impairment. Radiological parameters included tumour volume, physis-cyst distance, thickness of cyst cortex, and presence of intracystic septations. Mean follow-up was 35,6 months (24–71 months). Treatment was considered successful when the cyst volume decreased by a minimum of 10%, the bone cortex became thicker, and the distance to physis increased.ResultsMean age at presentation was 9.5 years (5.16–13.84 years). All ABC’s were primary and all patients underwent a single Surgiflo and alcohol session except for two (12.5%) who required a second session. All patients had a good clinical result at final follow-up. Satisfactory cyst healing was achieved in 11 cases according to radiological parameters. Tumour volume decreased from a mean of 122 cm3 (111 to 133) before injection to 86 cm3 (76 to 96) at last follow-up (p < 0.01). Physis-cyst distance increased from a mean of 1 cm (0.1 to 2) to 2.1 cm (0.5 to 4) at last follow-up (p < 0.01). Cortical thickness improved from 1 mm (0.5 to 1.5) to 2 mm (1 to 3.5) at last follow-up (p < 0.01).There were no treatment related complications. Surgery was performed in one patient having a C3 vertebra ABC after developing quadriparesis due to tumour progression.ConclusionSclerotherapy using Surgiflo and alcohol may be used as an efficient, safe and minimally invasive alternative for the treatment of primary ABCs.

Treatment of Aneurysmal Bone Cysts with Bioactive Glass in Children.

Aneurysmal bone cysts represent about 1% of primary bone tumors. The standard treatment is curettage, followed by local adjuvant treatments and bone grafting. The problem is the high recurrence rate. The purpose of this study was to evaluate retrospectively the use of bioactive glass as a filling material in the treatment of aneurysmatic bone cysts in children. A total of 18 consecutive children (mean 11.3 years at surgery; 10 males; 11 lower, 6 upper limb, 1 pelvis; 15 with primary surgery) with histologically proven primary aneurysmal bone cysts operated with curettage and bioactive glass filling between 2008 and 2013 were evaluated after a mean follow-up of 2.0 years (range, 0.7-5.1 years). Two (11%) patients showed evidence of aneurysmal bone cyst recurrence and both have been re-operated for recurrence. Bone remodeling was noted in all patients with remaining growth and no growth plate disturbances were recorded. Two patients needed allogeneic blood transfusion. No intraoperative or postoperative complications were recorded. We conclude that bioactive glass is a suitable filling material for children with primary aneurysmal bone cyst. Bioactive glass did not affect bone growth and no side effects were reported.

Shaped graft for aneurysmal bone cyst of upper limb bones

The optimal treatment of aneurysmal bone cyst remains challenging. The aim of this prospective study was to evaluate the results of using bone grafts shaped to the defects caused by aneurysmal bone cysts of upper limb bones. Fifteen patients (12 males and 3 females) with an average age of 12 years (range 6–16 years) were treated for aneurysmal bone cysts of upper limb bones by intralesional resection, argon beam coagulation and shaped bone graft. The grafts were harvested from 14 patients (11 fibulas and 3 iliac bones) and from the mother of one patient (proximal fibula). Osteosynthesis was required to stabilize the graft in four cases. The modified Enneking’s scoring system was used for functional evaluation. One patient developed partial recurrence at 6 months and required reoperation. Superficial wound infection was encountered in one patient. Shortening of the humeral segment was seen in two patients (1 and 1.5 cm) but without angular deformity. After a mean follow-up of 45 months (range 24–68 months), the mean functional score was 97.3%. This technique proved to be reliable in obtaining a well reconstructed and growing bone with no or minimal deformity and good function.

O etanol pode ser usado como adjuvante na curetagem ampla a fim de reduzir a taxa de reincidência de cisto ósseo aneurismático?

ObjectiveThe best treatment of aneurysmal bone cyst (ABC) is still unclear. This study aimed to evaluate the usefulness of extended curettage and ethanol as an adjuvant to reduce local recurrence of ABCs. MethodsRetrospectively, 68 cases treated for primary and secondary ABCs caused by benign tumors from 2003 to 2013 were enrolled to a follow‐up visit between one to ten years after the surgery. The treatment protocol was en‐bloc resection, biopsy and curettage, extended curettage consisted of curettage, high‐speed burring, ethanol 96%, and electrocauterization (combined four‐step alcohol‐using approach) followed by defect filling, consecutively. ResultsAmong 36 patients with primary ABCs (16 male, 20 female, mean age of 16 years, range 3–46 years), 29 cases were treated with the combined four‐step alcohol‐using approach, four patients with resection, and three with biopsy and curettage. Thirty‐two cases had secondary ABCs on benign lesions (17 male, 15 female). The recurrence rate was 5.88 in all primary and secondary ABC cases; two recurrences among 29 patients with primary ABCs (6.9%) and one recurrence among the 22 cases with secondary ABCs (4.5%). ConclusionsIt could be suggested that the combined four‐step alcohol‐using approach may result in a very low recurrence rate of primary and secondary ABC lesions.

WITHDRAWN: Management of aneurysmal bone cyst using non-vascularised fibula graft – A series of four cases

Aneurysmal bone cyst (ABC) is an uncommon pathological condition, which leads to weakening and fracture of the affected part of the bone. Radiologically, ABC is an eccentric, metaphyseal, expansile, lytic and non-neoplastic lesion of the bone, giving blown-out/ballooned/soap-bubble appearance. Though benign, malignant transformation is reported. It accounts for 1–6% of all primary bone tumours with incidence rate of 0.14% annually. Usually occurs during second decade of life and most common sites for the lesions are the tibia, femur, vertebra, pelvis, humerus and fibula. The various treatment modalities include selective arterial embolisation, en-bloc/wide marginal resection and curettage with phenol, liquid nitrogen, etc., use of sclerosing agents and use of autogenic/allogenic bone graft or polymethylmethacrylate, with or without osteosynthesis. There exists controversy regarding optimum treatment of ABC as recurrence rate ranges from 5–40% depending upon the treatment method used. Use of non-vascularised fibular strut graft yields good results as per many studies especially in large lesions. Hereby, we present four cases of ABC, treated by extended curettage or En bloc excision of lesions and reconstruction using fibular strut graft.

Efficacy and Safety of Selective Arterial Embolization in the Treatment of Aneurysmal Bone Cyst of the Mobile Spine: A Retrospective Observational Study.

A retrospective observational study. Our aim is to define the efficacy and safety of serial selective arterial embolization (SAE) in the treatment of aneurysmal bone cysts (ABCs), to explore potential treatment alternatives, and to define a therapeutic algorithm. ABC is a benign lesion with an unpredictable behavior. Its treatment is challenging especially in poorly accessible surgical areas, such as spine and pelvis. Currently, the first-line treatment of ABC is repeated SAE until healing. Other options have been used with variable success rates. From January 2004 to September 2015, 23 patients affected by ABC of the mobile spine have been treated with SAE and prospectively followed up by computed tomographic scan and magnetic resonance imaging. Signs of neurological deficit, complications, healing of the lesion, and clinical outcomes were registered.Signs of healing are defined as peripheral sclerotic bone rim formation, decrease of the ABC mass, disappearance of the double content image, and bone formation inside the ABC mass, associated with remission of pain. Twenty-three patients underwent SAE according to the protocol. Seventeen patients have healed. The number of procedures necessary to obtain healing (clinical and radiographic) varied from 1 to 10. No complication occurred during the procedure. Follow-up time ranged from 5 to 120 months after the last angiographic procedure. All 17 patients had complete relief of pain symptoms. Six patients did not respond to SAE, presenting a progressive clinical and radiographic worsening, and underwent other medical or minimally invasive treatments. Our study confirms the safety of SAE. The efficacy of the treatment was however lower than expected. SAE is indicated when pathological fracture or signs of cord damage are not detected. Infiltration with autologous bone marrow concentrate or administration of Denosumab is under investigation as alternative choices of treatment. 4.

Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient

Aneurysmal bone cysts (ABC) are benign bone tumors, which are highly vascularized. The main course of treatment is curettage followed by bone grafting or cement insertion. Still recurrence remains a main problem for patients. Denosumab is a monoclonal antibody, which acts as an inhibitor of the RANK/RANKL pathway, diminishing bone turnover. Recent case reports have shown that Denosumab can be a promising therapeutic agent for people suffering from therapy-resistant ABC. We report the case of a 35-year-old female patient presenting with a pronounced ABC of the pelvis. Since the tumor was inoperable, Denosumab was administered, leading to a significant shrinkage of the lesion, which allowed surgical intervention. Upon recurrence, Denosumab was restarted putting the patient once more into remission. Follow-up was four years overall with a clinical and radiological stable disease for fifteen months after final discontinuation of the monoclonal antibody. Therefore, our case further underlines the potential of Denosumab in the treatment of ABC.

Shaped graft for aneurysmal bone cyst of upper-limb bones

The optimal treatment of aneurysmal bone cyst remains challenging. The aim of this prospective study was to evaluate the results of using bone grafts shaped to the defects caused by aneurysmal bone cysts of upper limb bones. Fifteen patients (12 males and 3 females) with an average age of 12 years (range 6–16 years) were treated for aneurysmal bone cysts of upper limb bones by intralesional resection, argon beam coagulation and shaped bone graft. The grafts were harvested from 14 patients (11 fibulas and 3 iliac bones) and from the mother of one patient (proximal fibula). Osteosynthesis was required to stabilize the graft in four cases. The modified Enneking’s scoring system was used for functional evaluation. One patient developed partial recurrence at 6 months and required reoperation. Superficial wound infection was encountered in one patient. Shortening of the humeral segment was seen in two patients (1 and 1.5 cm) but without angular deformity. After a mean follow-up of 45 months (range 24–68 months), the mean functional score was 97.3%. This technique proved to be reliable in obtaining a well reconstructed and growing bone with no or minimal deformity and good function.

Treatment of aneurysmal bone cysts by percutaneous CT-guided injection of calcitonin and steroid.

To determine the efficacy and safety of percutaneous calcitonin and steroid injection in the treatment of aneurysmal bone cysts (ABCs). Our study was IRB-approved and HIPAA-compliant. We reviewed pre- and post-procedural imaging studies and medical records of all CT-guided percutaneous injections of ABCs with calcitonin and steroid performed at our institution between 2003 and 2015. Treatment success based on imaging was categorized as substantial (51-100%), partial (1-50%), or none (0%) by comparing radiographs of the lesion before and after treatment. Our study group comprised 9 patients (7female, 2male; mean age 19 ± 5 (range 12-25) years). ABCs were located in the pubis (n = 3), femur (n = 2), and humerus/scapula/ilium/sacrum (n = 1 for each). One patient did not have any clinical or imaging follow-up. For the other 8 patients, clinical and imaging follow-up ranged from 1 to 93months (mean 16 ± 29months). One patient had two injections, and 1 patient had three injections. Six out of eight patients (75%) had complete symptomatic relief and 2 patients (25%) had partial symptomatic relief after initial injection. Imaging follow-up revealed substantial imaging response in 4 out of 8 patients (50%). There was a partial imaging response in 2 patients (25%) and no imaging response in 2 out of 8 patients (25%), and all 4 of these patients had local recurrence. There were no complications. Percutaneous CT-guided injection of ABCs with calcitonin and steroid is a safe and effective treatment. Lack of imaging response may necessitate more aggressive treatment to minimize local recurrence.

Bone Marrow Injection for Treatment of Aneurysmal Bone Cyst

Study design: Patients had Aneurysmal bone cyst lesion that underwent to be treated by Injection of Autologous Bone Marrow Aspirates (ABM) and follow up of this case for the final results. Patients and Methods: Sixteen patients had had Aneurysmal bone cyst had been treated by ABM injections. Study have 16 patients 11 females (68.75 %) and 5 male (31.25 %). Age ranged from 3-14 years with average age 7.5 years. Number of injections for every patient ranged from 2-6 times with average 4.4 times. This study including 5 cases (31.25 %) with proximal femoral cyst, 9 cases (56.25 %) had tibial cyst (2 distal and 7 proximal tibiea) and 2 cases (12.5 %) had proximal humeral cyst. All patients treated by injection of Autologous Bone Marrow Aspirates which obtained from the iliac crest. The bone marrow aspirates was obtained percutaneous by bone marrow aspiration needle, According to follow up X-ray during injections we decide continuity of injections. Average size of the defect was 2.3 cm. and average amount bone marrow/inj. Was 10.2 cc. Results: Pain Score according to VAS ranged from 3-9 with average 5.7 which was improved to average 1.5 at final follow up. Healing time ranged from 21 - 90 days with average 42.2 days. Motion of the arm as patients can move their arm without pain was allowed. Weight bearing for the lower limbs also had been allowed as patients felt pain subsided even there is no complete healing radiological. Conclusion: Aneurysmal Bone cyst has risk for fracture and recurrence after various modalities of treatment. Bone marrow has the advantage of percutaneous treatment (minimal Invasive) and has no recurrence reported for the current study.

Can ethanol be used as an adjuvant to extended curettage in order to reduce the recurrence rate of aneurysmal bone cyst?

ObjectiveThe best treatment of aneurysmal bone cyst (ABC) is still unclear. This study aimed to evaluate the usefulness of extended curettage and ethanol as an adjuvant to reduce local recurrence of ABCs. MethodsRetrospectively, 68 cases treated for primary and secondary ABCs caused by benign tumors from 2003 to 2013 were enrolled to a follow-up visit between one to ten years after the surgery. The treatment protocol was en-bloc resection, biopsy and curettage, extended curettage consisted of curettage, high-speed burring, ethanol 96%, and electrocauterization (combined four-step alcohol-using approach) followed by defect filling, consecutively. ResultsAmong 36 patients with primary ABCs (16 male, 20 female, mean age of 16 years, range 3–46 years), 29 cases were treated with the combined four-step alcohol-using approach, four patients with resection, and three with biopsy and curettage. Thirty-two cases had secondary ABCs on benign lesions (17 male, 15 female). The recurrence rate was 5.88 in all primary and secondary ABC cases; two recurrences among 29 patients with primary ABCs (6.9%) and one recurrence among the 22 cases with secondary ABCs (4.5%). ConclusionsIt could be suggested that the combined four-step alcohol-using approach may result in a very low recurrence rate of primary and secondary ABC lesions.

Endoscope-assisted enucleation and guided bone regeneration of a recurrent aneurysmal bone cyst in the mandibular condyle

Aneurysmal bone cyst (ABC) is a locally destructive, expansive, benign bone disease which most commonly occurs in the metaphyseal region of the long bones of children and adolescents, only 1% to 3% of ABCs have been described in the jaws. The aim of this study was to explore the minimal invasive surgical technique of treating ABC occurring in the mandibular condyle. Here we present a 10-year-old girl with recurrent ABC in her left condyle and adjacent ramus. She was treated by curettage via an extraoral endoscopic-assisted surgical approach and guided bone regeneration. The patient had an uneventful postoperative period with no injury to the facial nerves and minimal scarring. No recurrence was found in 4 years (from 2011). Computed tomography (CT) showed bone formation and remodeling of the condyle and ramus. Endoscopic-assisted curettage combined with guided bone regeneration can achieve an ideal effect in the treatment of ABC of the mandibular condyle and ramus.

Aneurysmal bone cyst of C2 treated with novel anterior reconstruction and stabilization.

Aneurysmal bone cysts (ABC) form 1% of primary bone tumors. Reported incidence rates are no more than 1.4 to 1,00,000. ABC of spine frequently involves posterior elements and commonly affects the lumbar spine (45%). We present a case of C2 ABC for the challenges it poses due to the rarity of the lesion, tedious to access location, dilemmas relating to the suitable approach for tumor resection and technically demanding stabilization and reconstruction strategy post resection. Clinical data analysis was performed to discuss a method of novel anterior column reconstruction following resection of a C2 aneurysmal bone cyst in a 8 year old child with anterior and posterior elements being involved. An 8-year-old girl with an aneurysmal bone cyst of the C2 vertebra underwent staged surgery following pre-operative embolisation. First a posterior approach tumor excision with posterior instrumented fusion was performed. Following which, using a modified anterior retropharyngeal approach anterior tumor excision and fibular graft reconstruction between the C1 lateral mass and C2 body was performed. Complete tumor clearance and stable reconstruction was successfully achieved in our patient. Patient showed excellent clinical outcome with radiological fusion. Preoperative embolisation in the treatment of ABC has supplemental advantage by reducing blood loss. Modified anterior retropharyngeal approach allows satisfactory clearance for C1-2 lesion and fibular strut graft between the C1 lateral mass and C2 body can provide a stable graft placement with good chance of fusion. Instability and spinal deformity, whether preexisting or post-excision, should be corrected with reconstruction and stabilization to offer best chance of cure in such cases.

Percutaneous Doxycycline Treatment of Juxtaphyseal Aneurysmal Bone Cysts.

A recurrence rate of 19% to 23% has been reported in juxtaphyseal aneurysmal bone cysts (ABC) without en bloc resection or amputation. No percutaneous surgical techniques or drug treatments have demonstrated consistent bone healing with normal physeal growth and a recurrence rate of <19%. Doxycycline has properties that may make it an appropriate agent for percutaneous treatment of juxtaphyseal ABC in skeletally immature patients. We retrospectively reviewed 16 patients who underwent percutaneous treatment of ABCs with doxycycline from 2006 to 2011. The mean age was 7.1 years (range, 2 to 15 y). There were 16 treatment locations: humerus (9), tibia (3), fibula (2), femur (1), and ulna (1). Sixteen patients completed treatment involving 102 treatment sessions (2 to 14 sessions per patient). Treatment response was evaluated radiographically by measuring the lytic component, thickness of involved cortex, and signs of bony remodeling, and evidence of physeal growth arrest. Recurrence was indicated by new areas of lytic destruction after completion of treatment. The minimum follow-up was 18 months (mean, 39 mo). All 16 patients demonstrated reduction in lytic destruction, bony healing, and bony remodeling. One patient demonstrated recurrent minimal lytic destruction after 20 months of observation. Seven patients (7/16, 44%) demonstrated physeal ABC involvement; 5 of 7 patients healed with a physeal bone bridge, all ≤15% of the physeal surface area, 1 with mild central physeal deformity. All patients with focal transphyseal ABC involvement (4/4, 100%) demonstrated focal bone bridge after treatment. No patient had diffuse physeal growth arrest; only patients with intraphyseal or transphyseal ABC involvement had focal physeal growth arrest. In this series, patients undergoing percutaneous doxycycline treatment of juxtaphyseal ABCs demonstrated ABC healing and a recurrence rate of 6% at >18 months. Patients without physeal ABC involvement demonstrated no evidence of physeal growth arrest.

Aneurysmal bone cyst: A 19-case series managed by percutaneous sclerotherapy

IntroductionSclerotherapy offers an alternative to surgery for the treatment of aneurysmal bone cyst (ABC). The main objective of the present study was to assess the radiological efficacy of sclerotherapy in terms of ossification on MRI. Secondary objectives were to assess clinical efficacy on pain evaluation and to analyze recurrence and complications according to type of sclerosing agent and intraoperative imaging technique. Materials and methodsBetween 2006 and 2014, 19 patients (7 females, 12 males, aged 3 to 17 years) with ABC treated by sclerotherapy were included. Six received Ethibloc®, 9 Aetoxisclerol®, 2 liquid absolute alcohol, and 2 absolute alcohol gel. Assessment used fluoroscopy in 17 cases and CT in 2. Ossification was assessed on MRI and pain on a visual analog scale and HEDEN score. ResultsOssification was complete in 11 cases (84.6%) and partial in 2 (15.4%). Eighteen patients (94.7%) were pain-free at 3 months. There was no recurrence, at a minimum 2 years’ follow-up. One case of skin necrosis was observed, associated with use of liquid absolute alcohol; there was 1 case of arterial reflux of Ethibloc® under CT control. DiscussionSclerotherapy enables minimally invasive treatment of lesions that are deep, difficult of access to surgery and potentially damaging. Use of absolute alcohol gel and fluoroscopic control seems to improve the risk/benefit ratio, limiting complications by vascular extravasation of the sclerosing agent, thanks to real-time visualization of diffusion. Its clinical and radiological efficacy makes sclerotherapy and alternative primary treatment choice in ABC. Level of evidenceIV, retrospective study.

Treatment of aneurysmal bone cyst by curettage and hydrogen peroxide as an adjuvant without refilling of the resultant cavity

Background Aneurysmal bone cyst (ABC) is a rare tumor-like lesion with wide controversy as regards the perfect means of treatment and the way to manage the resulting bony cyst after curettage. Patients and methods The study included 24 patients: 13 were male and the mean age was 12.6 years (range: 6–26 years). Six cases were diagnosed as solid ABC, nine (37.5%) cases were in the proximal femur. All cases were treated by thorough curettage followed by washing the cyst with hydrogen peroxide for 5 min. No bone graft or substitute was used as a filler of the cysts, except strut fibular graft, which was used to stabilize weak cysts in nine cases. Plaster cast was used in 11 cases for external fixation. Follow-up ranged from 12 to 46 months (mean: 25 months). Results All cysts healed without pathological fracture. There was no local recurrence until the end of follow-up. All patients returned back to normal life. Conclusion Thorough curettage with lavage of the cyst with hydrogen peroxide could be an acceptable method of treatment of ABC without the need of refilling of the resulting cavity.

Bone marrow injection for the treatment of aneurysmal bone cyst

Bone marrow injection for the treatment of aneurysmal bone cyst

Fibular graft for reconstruction of proximal femoral aneurysmal bone cysts

Background The treatment options of aneurysmal bone cyst might change according to patient’s age, location, and type of lesion. Curettage and insertion of bone graft or polymethyl methacrylate are the principal techniques used. Patients and methods Eight patients (five male and three female; aged 8–14 years, with a mean age of 11 years) were treated with fibular autograft and iliac graft for the treatment of aneurysmal bone cyst in the proximal femur. Plain radiography and clinical assessment were performed through the whole follow-up period between 20 and 48 months (with a mean of 36 months). The musculoskeletal tumor society scoring system for limb salvage for the lower limb was used for clinical evaluation. Results Clinically, seven out of eight patients had excellent results according to the musculoskeletal tumor society scoring system for limb salvage for the lower limb. One case had postoperative pathological fracture after beginning weight bearing. Fibular grafts were fully incorporated into the recipient site within 12–16 months, with a mean incorporation time of 13 months. The graft donor site showed some minor problems such as leg discomfort and heel pain. Conclusion Curettage and an autogenous nonvascularized fibular graft is a good technique to treat benign cystic lesions of the proximal femur in relatively young patients. It is recommended to externally protect the limb with plaster of Paris. Hydrogen peroxide lavage was used to control local recurrence.